Development of a novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism

2016 Fiscal Year Final Research Report

• Project/Area Number: 25713046
• Research Category: Grant-in-Aid for Young Scientists (A)
• Allocation Type: Partial Multi-year Fund
• Research Field: Radiation science
• Research Institution: Kyoto Pharmaceutical University (2016); Kyoto University (2013-2015)
• Principal Investigator: KIMURA HIROYUKI 京都薬科大学, 薬学部, 准教授 (50437240)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Keywords: 原発性アルドステロン症 / アルドステロン産生腺腫 / PET/SPECT用分子イメージングプローブ / CYP11B2選択的化合物

Outline of Final Research Achievements

Primary aldosteronism (PA) is the most common and surgically curable form of endocrine hypertension, accounting for 5%-10% of all patients with hypertension. Approximately 60% patients with PA exhibit bilateral form causing aldosterone hypersecretion and require medical treatment with mineralocorticoid receptor antagonists. The remaining 40% exhibit the unilateral form causing hypersecretion, e.g., aldosterone-producing adenoma (APA); in these patients, hypertension and hyperaldosteronism can be cured by unilateral laparoscopic adrenalectomy. Therefore, an accurate method for distinguishing unilateral from bilateral adrenal disease is critical for patients who wish to pursue the surgical option. Aldosterone synthase (CYP11B2) is responsible for the majority of cases clinically diagnosed as primary aldosteronism. CYP11B2 is highly homologous to 11β-hydroxylase (CYP11B1). In this study, we have developed a PET/SPECT imaging probe with higher selectivity for CYP11B2 than CYP11B1.

Free Research Field

放射性医薬品学